Wednesday, July 8, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “trastuzumab” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 35
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 35 pipeline programs matching "trastuzumab" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

35 results for “trastuzumab” Back to intelligence hub

Search results

Page 2 of 2
  1. Trastuzumab in Combination with TS-ONE and cisplatin

    Hospital Authority, Hong Kong

    Gastric Cancer

    phase 2 small molecule active

    1 trial
  2. pyrotinib and trastuzumab in combinition with neoadjuvant chemotherapy

    The First People's Hospital of Lianyungang

    HER2-positive Breast Cancer

    phase 2 small molecule active

    1 trial
  3. Subcutaneous Trastuzumab Deruxtecan Phase 1 Trial.

    Daiichi Sankyo

    Advanced Solid Tumor

    phase 1 other active

    1 trial
  4. Trastuzumab

    Hoffmann-La Roche

    Early Breast Cancer

    phase 1 small molecule completed

    1 trial
  5. Trastuzumab Deruxtecan

    Daiichi Sankyo

    Recurrent or Metastatic Solid Tumors

    phase 1 small molecule active

    1 trial
  6. trastuzumab [Herceptin]

    Hoffmann-La Roche

    Healthy Volunteer

    phase 1 small molecule completed

    1 trial
  7. Trastuzumab Rezetecan

    The First People's Hospital of Lianyungang

    Breast Cancer

    approved small molecule active

    1 trial
  8. trastuzumab [Herceptin]

    Hoffmann-La Roche

    Gastric Cancer

    approved small molecule terminated

    1 trial
  9. 89Zr-trastuzumab

    United Therapeutics Europe Ltd

    Breast Cancer Metastases

    other completed

    1 trial
  10. Paclitaxel oral solution plus Subcutaneous Pertuzumab/Trastuzumab

    The First People's Hospital of Lianyungang

    Breast Cancers

    small molecule active

    1 trial
  11. Paclitaxel oral solution plus Subcutaneous Pertuzumab/Trastuzumab

    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

    Breast Cancers

    small molecule active

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.